{
    "nctId": "NCT05803889",
    "briefTitle": "Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer",
    "officialTitle": "Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer - PROTECT-COEUR",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Studying the impact of chemotherapy combining EC and Tax on myocardial deformations (at rest and at submaximal effort) in order to identify the kinetic of systolic and diastolic dysfunctions.",
    "eligibilityCriteria": "Inclusion Criteria:\n\nEpirubicin-cyclophosphamide + paclitaxel group:\n\n* Female \u2265 18 years\n* Stage I to III breast cancer\n* Patient being planned for (neo)adjuvant therapy combining EC and Taxol on a weekly basis\n* Enrolled in a social security plan\n* Able to speak, read and understand French\n\nTrastuzumab group:\n\n* Female \u2265 18 years of age\n* Stage I to III breast cancer\n* Patient treated with trastuzumab\n* Enrolled in a social security plan\n* Able to speak, read and understand French\n\nExclusion Criteria:\n\nFor both groups: Epirubicin-cyclophosphamid + paclitaxel group and trastuzumab group\n\n* Implantation of a pacemaker\n* Contraindications to exercise\n* Protected adult\n* Psychiatric, musculoskeletal or neurological problems\n* Pregnant or breastfeeding woman\n* Uncontrolled high blood pressure\n* Body Mass Index \\> 35 kg/m\u00b2",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}